TMDX

Transmedics Group, Inc. Health Care Electromedical & Electrotherapeutic Apparatus Russell 3000

$65.99Close $2.3BMarket cap $62.04 – $150.4252-week range Nov 5, 2026Next report · after the close

Highlights

Cautions

Not in an uptrend 0 of 8 trend conditions
Lagging the market RS 6 · weaker than 94% of stocks over 12 months
Far from its high 56% below its 52-week high
Distribution down-day volume 1.5× up-day volume over 50 sessions
Earnings shrinking EPS −58% year on year
Results soon Nov 5, 2026, in 4 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 4, 2026

Off 12-month high 56%

1wk 6.7% price change

1mo 20.9% price change

12-month return 51% market up 11% · its own down 62%

F-score 7 / 9 Strong

Altman Z 3.43 Low risk

P/E 11.9× price / earnings

PEG 0.03 P/E / EPS growth

P/B 4.8× price / book

Earnings yield 6.1% EBIT / enterprise value

Cheaper than 62% of the market · cheap

Revenue growth 37% year on year

EPS growth 58% latest quarter · +10 pts

Sales growth 21% latest quarter · -0 pts

ROE 54% return on equity

Free cash margin 22% $133.6M FCF

D/E — long-term debt / equity

Net debt / EBITDA -3.6× net cash

Interest cover —EBIT / interest

Piotroski tests

short-term liquidity weakened
issued more shares
profitable on its assets
generating cash from operations
profitability improving
profits backed by cash
reduced long-term debt
gross margin widened
assets working harder

Repair signals

FCF turned positive ($-81M → $134M)

Trade setup

ATR% 5.5% $3.64 a day · 2×ATR $58.71

RS 6 / 99 vs the universe

Trend 0 / 8 trend template

Relative volume 1.2× vs 50-day average

Up/down volume 0.66 50 sessions

Implied move — no option chain · report Nov 5, 2026

Trend template · 0 of 8

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged

No restatement or impairment
Equity positive
Interest covered
No material dilution
Profits tracking cash
Margins and revenue not shrinking

Last reported Aug 4, 2026

Results reaction Aug 4, 2026-8% vs market2 sessions after results

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $605.5M +37% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $190.3M +436% on FY2024

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $133.6M back to a profit

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Gross 60%
Net 31%
Free cash 22%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 34.27m +26.1% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$28.4M	$31.4M	$93.5M	$241.6M	$441.5M	$605.5M
Gross margin	59%	67%	70%	64%	59%	60%
Operating income	-$26.4M	-$39.4M	-$31.4M	-$28.7M	$37.5M	$108.6M
Net income	-$28.7M	-$44.2M	-$36.2M	-$25.0M	$35.5M	$190.3M
Net margin	-101%	-141%	-39%	-10%	8%	31%
Earnings per share	-$1.16	-$1.60	-$1.22	-$0.77	$1.01	$4.69
Free cash flow	-$30.7M	-$32.4M	-$57.7M	-$164.9M	-$80.9M	$133.6M
Free cash margin	-108%	-103%	-62%	-68%	-18%	22%
Cash	$24.6M	$25.6M	$201.2M	$394.8M	$337.1M	$488.9M
Long-term debt	$34.7M	$35.2M	$58.7M	—	—	—
Shareholders' equity	$103.9M	$67.9M	$187.4M	$137.2M	$228.6M	$473.1M
Shares outstanding	27.18m	27.79m	32.14m	32.67m	33.62m	34.27m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 4, 2026	Quarterly ↗	Jun 30, 2026	35d
May 5, 2026	Quarterly ↗	Mar 31, 2026	35d
Feb 24, 2026	Annual ↗	Dec 31, 2025	55d
Oct 29, 2025	Quarterly ↗	Sep 30, 2025	29d
Jul 30, 2025	Quarterly ↗	Jun 30, 2025	30d
May 8, 2025	Quarterly ↗	Mar 31, 2025	38d
Feb 27, 2025	Annual ↗	Dec 31, 2024	58d
Oct 29, 2024	Quarterly ↗	Sep 30, 2024	29d
Aug 1, 2024	Quarterly ↗	Jun 30, 2024	32d
May 2, 2024	Quarterly ↗	Mar 31, 2024	32d
Feb 27, 2024	Annual ↗	Dec 31, 2023	58d
Nov 8, 2023	Quarterly ↗	Sep 30, 2023	39d

Current reports

Filed	Disclosed
Sep 10, 2026	Director or officer change · Regulation FD ↗
Aug 4, 2026	Results ↗
May 21, 2026	Shareholder vote ↗
May 5, 2026	Results ↗
Feb 27, 2026	Results ↗
Feb 24, 2026	Results ↗
Feb 4, 2026	Director or officer change ↗
Jan 12, 2026	Material agreement · Other events ↗
Oct 29, 2025	Results ↗
Oct 6, 2025	Acquisition or disposal ↗
Jul 30, 2025	Results ↗
May 23, 2025	Shareholder vote ↗